{"entity":{"id":"2008","kind":"year","name":"2008 in oncology","aka":["2008"],"tldr":"Everything OnCo dates to 2008: 150 entries, 37 papers listed on people's pages, 34 landmarks, 33 papers and 16 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"150 dated entries in OnCo fall in 2008: 37 papers listed on people's pages, 34 landmarks, 33 papers, 16 approvals, 8 companies founded, 8 trials reported, 6 journals founded, 6 technologies, 1 law or regulation and 1 regulatory event.\n\nOf those, 1 to the day and 149 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2007","2009"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2008,"events":[{"group":"approval","date":"2008","precision":"year","title":"Aprepitant (and fosaprepitant) approved in US","note":"Fosaprepitant intravenous prodrug for the same indications","from":"aprepitant","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Bendamustine approved in US","note":"CLL; indolent B-cell NHL progressed within 6 months of rituximab","from":"bendamustine","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Bortezomib approved in US","note":"Newly diagnosed myeloma","from":"bortezomib","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Degarelix approved in US","note":"Advanced prostate cancer","from":"degarelix","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Eltrombopag approved in US","note":"Chronic immune thrombocytopenia with insufficient response to corticosteroids, immunoglobulins or splenectomy.","from":"eltrombopag","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Fentanyl (transmucosal, for breakthrough cancer pain) approved in EU","note":"Breakthrough pain in adults receiving maintenance opioid therapy for chronic cancer pain. Effentora authorised 4 Apr 2008 (Phoenix Labs); Instanyl 20 Jul 2009 (Istituto Gentili); P...","from":"fentanyl","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Filgrastim (G-CSF) approved in EU","note":"First biosimilar filgrastims (Tevagrastim, Ratiograstim, Biograstim); Zarzio 2009","from":"filgrastim","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Granisetron approved in US","note":"Transdermal system for chemotherapy of up to five consecutive days (Sancuso)","from":"granisetron","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Histamine dihydrochloride approved in EU","note":"Maintenance with interleukin-2 for adults with AML in first remission (exceptional circumstances)","from":"histamine-dihydrochloride","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Methylnaltrexone approved in EU","note":"Opioid-induced constipation in advanced illness receiving palliative care when laxatives are insufficient (Relistor)","from":"methylnaltrexone","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Methylnaltrexone approved in US","note":"Opioid-induced constipation in advanced illness receiving palliative care (chronic non-cancer pain and oral tablets added 2014 to 2016)","from":"methylnaltrexone","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Nab-paclitaxel approved in EU","note":"Metastatic breast cancer; later pancreatic (2013) and non-small-cell lung cancer (2015). EMA EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane","from":"nab-paclitaxel","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Pemetrexed approved in US","note":"Non-squamous NSCLC first line","from":"pemetrexed","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Plerixafor approved in US","note":"Stem cell mobilisation with filgrastim for autologous transplantation in NHL and multiple myeloma","from":"plerixafor","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Romiplostim approved in US","note":"Immune thrombocytopenia with insufficient response to corticosteroids, immunoglobulins or splenectomy.","from":"romiplostim","refs":[]},{"group":"approval","date":"2008","precision":"year","title":"Thalidomide approved in EU","note":"Untreated multiple myeloma ≥65 or transplant-ineligible, with melphalan-prednisone","from":"thalidomide","refs":[]},{"group":"company","date":"2008","precision":"year","title":"Alphamab Oncology founded","note":"Suzhou","from":"alphamab","refs":[]},{"group":"company","date":"2008","precision":"year","title":"ANZUP Cancer Trials Group founded","note":"Sydney","from":"anzup","refs":[]},{"group":"company","date":"2008","precision":"year","title":"Cancer Prevention Pharmaceuticals founded","note":"Tucson, AZ","from":"cancer-prevention-pharmaceuticals","refs":[]},{"group":"company","date":"2008","precision":"year","title":"Lumicell founded","note":"Newton, MA","from":"lumicell","refs":[]},{"group":"company","date":"2008","precision":"year","title":"Netris Pharma founded","note":"Lyon","from":"netris-pharma","refs":[]},{"group":"company","date":"2008","precision":"year","title":"Profound Medical founded","note":"Mississauga, ON","from":"profound-medical","refs":[]},{"group":"company","date":"2008","precision":"year","title":"Rhythm Pharmaceuticals founded","note":"Boston, Massachusetts","from":"rhythm-pharmaceuticals","refs":[]},{"group":"company","date":"2008","precision":"year","title":"Xuanzhu Biopharmaceutical founded","note":"Beijing","from":"xuanzhu-biopharmaceutical","refs":[]},{"group":"history","date":"2008","precision":"year","title":"163 resected MCNs: cancer in 17.5 percent, all 40 mm or larger or with nodules","note":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","from":"mcn-associated-carcinoma","refs":["distal-pancreatectomy"]},{"group":"history","date":"2008","precision":"year","title":"ALK mutations identified as a hereditary and somatic driver","note":"Neuroblastoma (paediatric)","from":"neuroblastoma","refs":["alk"]},{"group":"history","date":"2008","precision":"year","title":"ANGIOTAX: weekly paclitaxel established as active in angiosarcoma","note":"Angiosarcoma","from":"angiosarcoma","refs":["angiotax","paclitaxel"]},{"group":"history","date":"2008","precision":"year","title":"ANGIOTAX: weekly paclitaxel in angiosarcoma","note":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma). Penel and colleagues, JCO, phase 2.","from":"vascular-tumours","refs":["paclitaxel"]},{"group":"history","date":"2008","precision":"year","title":"Castration-resistant disease is proved to be still hormone driven","note":"Prostate cancer. Attard's phase 1 of abiraterone in 21 men resistant to multiple hormonal therapies produced prostate-specific antigen falls of at least 50 percent in 12 of them, l...","from":"prostate","refs":["paper-attard-abiraterone-phase-1-cyp17-jco-2008"]},{"group":"history","date":"2008","precision":"year","title":"Claudin 18.2 identified as a tumour-exposed target (Sahin and colleagues)","note":"Claudin 18.2-positive gastric cancer","from":"gastric-cldn18-2-positive","refs":[]},{"group":"history","date":"2008","precision":"year","title":"Core signalling pathways from the first pancreatic exomes","note":"Pancreatic ductal adenocarcinoma. Twenty-four cancers carried an average of 63 alterations hitting twelve pathways in 67 to 100% of tumours.","from":"pancreatic","refs":["paper-jones-pancreatic-core-pathways-science-2008","kras"]},{"group":"history","date":"2008","precision":"year","title":"EORTC 55874: adjuvant pelvic radiotherapy does not improve survival in uterine sarcoma","note":"Uterine sarcoma","from":"uterine-sarcoma","refs":[]},{"group":"history","date":"2008","precision":"year","title":"EXPeRT founded","note":"Rare cancers of childhood (NCI PDQ umbrella). European Cooperative Study Group for Paediatric Rare Tumours pools national registries (Italy, Germany, France, Poland, UK).","from":"rare-childhood-cancers","refs":[]},{"group":"history","date":"2008","precision":"year","title":"EXTREME defines first-line therapy for recurrent/metastatic disease","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":["extreme"]},{"group":"history","date":"2008","precision":"year","title":"EXTREME: cetuximab with platinum-fluorouracil first line","note":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","from":"hpv-negative-head-and-neck-cancer","refs":["extreme"]},{"group":"history","date":"2008","precision":"year","title":"EXTREME: first survival gain in recurrent disease","note":"Recurrent or metastatic head and neck squamous cell carcinoma","from":"recurrent-metastatic-hnscc","refs":["extreme"]},{"group":"history","date":"2008","precision":"year","title":"Fukase trial: Helicobacter pylori eradication reduces metachronous cancer after endoscopic resection","note":"Early gastric cancer","from":"early-gastric-cancer","refs":[]},{"group":"history","date":"2008","precision":"year","title":"German NB97: spontaneous regression in about half of observed infant tumours","note":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","from":"neuroblastoma-low-risk","refs":[]},{"group":"history","date":"2008","precision":"year","title":"GROINSS-V I: sentinel node biopsy is safe in early vulvar cancer","note":"HPV-associated vulvar squamous cell carcinoma","from":"hpv-associated-vulvar-cancer","refs":["sentinel-node"]},{"group":"history","date":"2008","precision":"year","title":"GROINSS-V I: sentinel node biopsy safe in early vulvar cancer","note":"Vulvar cancer","from":"vulvar","refs":["sentinel-node"]},{"group":"history","date":"2008","precision":"year","title":"Histology chooses the drug, and the adjuvant rule is fixed","note":"Lung cancer (all types). Pemetrexed beat gemcitabine in adenocarcinoma (12.6 against 10.9 months) and lost in squamous disease (9.4 against 10.8); LACE pooled 4,584 resected patien...","from":"lung-cancer","refs":["paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008","paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008"]},{"group":"history","date":"2008","precision":"year","title":"IDH1 mutations discovered in glioma","note":"Glioma & glioblastoma. Parsons/Vogelstein glioblastoma genome sequencing; reclassification follows.","from":"glioblastoma","refs":["idh"]},{"group":"history","date":"2008","precision":"year","title":"IDH1 mutations found in glioma","note":"Astrocytoma, IDH-mutant (grades 2 to 4). Parsons and colleagues sequence glioblastoma exomes (Science) and find IDH1 mutations concentrated in younger patients and secondary tumour...","from":"idh-mutant-astrocytoma","refs":["idh"]},{"group":"history","date":"2008","precision":"year","title":"INT-0133: mifamurtide improves overall survival; EU approval 2009","note":"Osteosarcoma","from":"osteosarcoma","refs":["mifamurtide"]},{"group":"history","date":"2008","precision":"year","title":"Intra-arterial melphalan via ophthalmic artery (Abramson)","note":"Retinoblastoma","from":"retinoblastoma","refs":["melphalan"]},{"group":"history","date":"2008","precision":"year","title":"KIAA1549-BRAF fusion discovered","note":"Paediatric low-grade glioma. Tandem duplication at 7q34 found in most pilocytic astrocytomas (Jones and colleagues), defining pLGG as a MAPK-pathway disease.","from":"paediatric-low-grade-glioma","refs":["braf","ras-mapk"]},{"group":"history","date":"2008","precision":"year","title":"KRAS as a negative predictive biomarker","note":"Colorectal cancer. Cetuximab improved survival only in K-ras wild-type tumours (9.5 against 4.8 months) and did nothing in mutant ones, creating the first negative predictive bioma...","from":"colorectal","refs":["paper-karapetis-kras-cetuximab-colorectal-nejm-2008","kras"]},{"group":"history","date":"2008","precision":"year","title":"KRAS mutations shown to predict failure of cetuximab and panitumumab","note":"KRAS G12C-mutant colorectal cancer","from":"kras-g12c-colorectal","refs":["cetuximab","panitumumab","kras"]},{"group":"history","date":"2008","precision":"year","title":"LACE meta-analysis: adjuvant cisplatin chemotherapy adds about 5 percent to five-year survival","note":"Resectable stage I to III non-small-cell lung cancer","from":"resectable-nsclc","refs":["cisplatin","vinorelbine"]},{"group":"history","date":"2008","precision":"year","title":"Merkel cell polyomavirus discovered","note":"Merkel cell carcinoma. Feng, Chang and Moore find clonally integrated MCPyV in most MCC using digital transcriptome subtraction.","from":"merkel-cell-carcinoma","refs":[]},{"group":"history","date":"2008","precision":"year","title":"MIPI prognostic index","note":"Mantle cell lymphoma","from":"mantle-cell-lymphoma","refs":[]},{"group":"history","date":"2008","precision":"year","title":"Propranolol for infantile haemangioma","note":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma). Léauté-Labrèze and colleagues, NEJM: serendipitous discovery.","from":"vascular-tumours","refs":[]},{"group":"history","date":"2008","precision":"year","title":"RTOG 98-11: mitomycin-based chemoradiotherapy beats induction cisplatin","note":"Localised anal squamous cell carcinoma (stage I to III)","from":"localised-anal-cancer","refs":["mitomycin"]},{"group":"history","date":"2008","precision":"year","title":"SHARP: sorafenib is the first drug to extend survival in advanced HCC","note":"Advanced hepatocellular carcinoma (BCLC C)","from":"hcc-advanced","refs":["sharp","sorafenib"]},{"group":"history","date":"2008","precision":"year","title":"Tang classification separates typical goblet cell carcinoid from adenocarcinoma ex goblet cell carcinoid","note":"Goblet cell adenocarcinoma of the appendix","from":"goblet-cell-adenocarcinoma","refs":[]},{"group":"history","date":"2008","precision":"year","title":"The only randomised trial of Mohs surgery reports at five years","note":"Skin cancer (all types). Mohs surgery better for recurrent facial basal cell carcinoma (2.4 against 12.1 per cent) and not significantly better for primary tumours; the ten-year re...","from":"skin-cancer","refs":["mohs-versus-excision-facial-bcc"]},{"group":"history","date":"2008","precision":"year","title":"The residual disease paradox and the brain metastasis rate","note":"Triple-negative breast cancer (TNBC). Liedtke: pathological complete response 22 vs 11 percent yet worse survival, driven by residual disease.","from":"tnbc","refs":["paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008","paper-lin-tnbc-cns-metastases-dfci-cancer-2008","brain-metastases"]},{"group":"history","date":"2008","precision":"year","title":"WHO names BPDCN","note":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN). Reclassified from 'CD4+/CD56+ haematodermic neoplasm' as a distinct entity.","from":"bpdcn","refs":[]},{"group":"journal","date":"2008","precision":"year","title":"Cancer prevention research founded","note":"American Association for Cancer Research","from":"cancer-prevention-research","refs":[]},{"group":"journal","date":"2008","precision":"year","title":"Hematology/oncology and stem cell therapy founded","note":"Wolters Kluwer Medknow","from":"hematology-oncology-and-stem-cell-therapy","refs":[]},{"group":"journal","date":"2008","precision":"year","title":"Journal of gynecologic oncology founded","note":"Asian Society of Gynecologic Oncology","from":"journal-of-gynecologic-oncology","refs":[]},{"group":"journal","date":"2008","precision":"year","title":"Journal of hematology & oncology founded","note":"BMC (Springer Nature)","from":"journal-of-hematology-and-oncology","refs":[]},{"group":"journal","date":"2008","precision":"year","title":"Journal of medical imaging and radiation oncology founded","note":"Wiley","from":"journal-of-medical-imaging-and-radiation-oncology","refs":[]},{"group":"journal","date":"2008","precision":"year","title":"Pigment cell & melanoma research founded","note":"Wiley","from":"pigment-cell-and-melanoma-research","refs":[]},{"group":"law","date":"2008","precision":"year","title":"GINA (Genetic Information Nondiscrimination Act 2008)","note":"United States, statute.","from":"gina","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"A history of cancer chemotherapy","note":"DeVita VT, Chu E. Cancer Research.","from":"paper-devita-cancer-res","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"ANGIOTAX: phase 2 trial of weekly paclitaxel for unresectable angiosarcoma","note":"Penel N, Bui BN, Bay JO, et al. Journal of Clinical Oncology.","from":"paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Basal cell carcinomas: attack of the hedgehog","note":"Epstein EH. Nature Reviews Cancer.","from":"paper-epstein-nat-rev-cancer","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial","note":"Hess V, Glimelius B, Grawe P, et al. The Lancet Oncology.","from":"paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Cancer as an overhealing wound: an old hypothesis revisited","note":"Schäfer M, Werner S. Nature reviews. Molecular cell biology.","from":"paper-schafer-nat-rev-mol-cell-biol","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","note":"Atchley DP, Albarracin CT, Lopez A, et al. Journal of Clinical Oncology.","from":"paper-atchley-brca-status-triple-negative-jco-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris","note":"Boveri T. Journal of cell science.","from":"paper-boveri-j-cell-sci","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","note":"Jones S, Zhang X, Parsons DW, et al. Science.","from":"paper-jones-pancreatic-core-pathways-science-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","note":"Khorana AA, Kuderer NM, Culakova E, et al. Blood.","from":"paper-khorana-blood","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Efficient tumour formation by single human melanoma cells","note":"Quintana E, Shackleton M, Sabel MS, et al. Nature.","from":"paper-quintana-nature","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"EXTREME: platinum-based chemotherapy plus cetuximab in recurrent or metastatic head and neck cancer","note":"Vermorken JB, Mesia R, Rivera F, et al. New England Journal of Medicine.","from":"paper-extreme-vermorken-nejm-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"GROINSS-V: sentinel node dissection is safe in early-stage vulvar cancer","note":"Van der Zee AG, Oonk MH, De Hullu JA, et al. Journal of Clinical Oncology.","from":"paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Jemal 2008: Cancer statistics, 2008","note":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. CA: A Cancer Journal for Clinicians.","from":"paper-jemal-cancer-statistics-2008-cacancer-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","note":"Karapetis CS, Khambata-Ford S, Jonker DJ, et al. New England Journal of Medicine.","from":"paper-karapetis-kras-cetuximab-colorectal-nejm-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet","note":"Saper RB, Phillips RS, Sehgal A, et al. JAMA.","from":"paper-saper-jama","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","note":"Pignon JP, Tribodet H, Scagliotti GV, et al. Journal of Clinical Oncology.","from":"paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Mani 2008: the epithelial-mesenchymal transition generates cells with properties of stem cells","note":"Mani SA, Guo W, Liao MJ, et al. Cell.","from":"paper-mani-emt-stem-cell-properties-cell-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial","note":"Kutner JS, Smith MC, Corbin L, et al. Annals of Internal Medicine.","from":"paper-kutner-ann-intern-med","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Methylnaltrexone for opioid-induced constipation in advanced illness (MNTX 302)","note":"Thomas J, Karver S, Cooney GA, et al. New England Journal of Medicine.","from":"paper-mntx-302-thomas-nejm-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Mistletoe therapy in oncology","note":"Horneber MA, Bueschel G, Huber R, et al. The Cochrane database of systematic reviews.","from":"paper-horneber-cochrane-database-syst-rev","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Phase 1 trial of abiraterone acetate confirms that castration-resistant prostate cancer commonly remains hormone driven","note":"Attard G, Reid AH, Yap TA, et al. Journal of Clinical Oncology.","from":"paper-attard-abiraterone-phase-1-cyp17-jco-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cance...","note":"Scagliotti GV, Parikh P, von Pawel J, et al. Journal of Clinical Oncology.","from":"paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based stu...","note":"Prado CM, Lieffers JR, McCargar LJ, et al. The Lancet Oncology.","from":"paper-prado-lancet-oncol","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors","note":"Elkins G, Marcus J, Stearns V, et al. Journal of Clinical Oncology.","from":"paper-elkins-j-clin-oncol","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","note":"Liedtke C, Mazouni C, Hess KR, et al. Journal of Clinical Oncology.","from":"paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"SHARP: sorafenib in advanced hepatocellular carcinoma","note":"Llovet JM, Ricci S, Mazzaferro V, et al. New England Journal of Medicine.","from":"paper-sharp-sorafenib-nejm-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Single-strand break repair and genetic disease","note":"Caldecott KW. Nature reviews. Genetics.","from":"paper-caldecott-nat-rev-genet","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","note":"Lin NU, Claus E, Sohl J, et al. Cancer.","from":"paper-lin-tnbc-cns-metastases-dfci-cancer-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas","note":"Herschkowitz JI, He X, Fan C, Perou CM. Breast Cancer Research.","from":"paper-herschkowitz-rb1-loss-basal-like-bcr-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Theories of carcinogenesis: an emerging perspective","note":"Sonnenschein C, Soto AM. Seminars in cancer biology.","from":"paper-sonnenschein-semin-cancer-biol","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Translational research: crossing the valley of death","note":"Butler D. Nature.","from":"paper-butler-nature","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","note":"Amado RG, Wolf M, Peeters M, et al. Journal of Clinical Oncology.","from":"paper-kras-colorectal-j-clin-oncol-2008","refs":[]},{"group":"paper","date":"2008","precision":"year","title":"Wisnoski 2008: 672 patients with acinar cell carcinoma of the pancreas, a population-based comparison to pancreatic adenocarcinoma","note":"Wisnoski NC, Townsend CM, Nealon WH, Freeman JL, Riall TS. Surgery.","from":"paper-wisnoski-acinar-cell-carcinoma-672-patients-seer-surgery-2008","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","note":"JAMA","from":"anthony-damico","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer (JCOG 9501)","note":"NEJM","from":"mitsuru-sasako","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome","note":"Nature","from":"timothy-ley","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease","note":"American Journal of Respiratory Cell and Molecular Biology","from":"yasuyuki-nasuhara","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study","note":"Lancet","from":"jean-philippe-spano","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Emergence of MRSA in positive blood cultures from patients with febrile neutropenia—a cause for concern","note":"Supportive Care in Cancer","from":"patrick-morris","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis","note":"JAMA","from":"kenneth-tanabe","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia","note":"Science","from":"james-r-downing","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Glycogen Synthase Kinase-3 and Cancer: Good Cop, Bad Cop?","note":"Cancer Cell","from":"jim-woodgett","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Human natural killer cells","note":"Blood","from":"michael-caligiuri","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Hydrocortisone therapy for patients with septic shock","note":"New England Journal of Medicine","from":"yoram-weiss","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Identification of ALK as a major familial neuroblastoma predisposition gene","note":"Nature","from":"john-maris","refs":["yael-mosse"]},{"group":"person-paper","date":"2008","precision":"year","title":"Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing","note":"Nature Genetics","from":"matthew-hurles","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Innate immunity and intestinal microbiota in the development of Type 1 diabetes","note":"Nature","from":"jeffrey-bluestone","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Laparoscopic and Robotic Assisted Radical Cystectomy for Bladder Cancer: A Critical Analysis","note":"European Urology","from":"georges-pascal-haber","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Leiomiossarcoma primário de adrenal","note":"Arquivos Brasileiros de Endocrinologia & Metabologia","from":"flavio-tomasich","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestin...","note":"Journal of Clinical Oncology","from":"charles-blanke","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Marginal Zone Lymphomas","note":"Hematology/Oncology Clinics of North America","from":"franco-cavalli","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells","note":"International Journal of Cancer","from":"fan-daiming","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","note":"JCO","from":"james-yao","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Patient Benefit From Endoscopically Assisted Fixation of Condylar Neck Fractures—A Randomized Controlled Trial","note":"Journal of Oral and Maxillofacial Surgery","from":"chen-chien-tzung","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors","note":"Clinical Cancer Research","from":"ruth-plummer","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumor...","note":"Journal of Clinical Oncology","from":"charles-blanke","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer","note":"New England Journal of Medicine","from":"andrzej-kawecki","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer (EXTREME)","note":"NEJM","from":"jan-vermorken","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","note":"Journal of Clinical Oncology","from":"priya-rastogi","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Primary atrial fibrosarcoma of the heart","note":"Cardiovascular Pathology","from":"paul-herijgers","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells","note":"The Journal of Immunology","from":"sandra-demaria","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Regulatory T cells and immune tolerance","note":"Cell","from":"shimon-sakaguchi","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Retrospective Analysis of Locally Advanced Noninflammatory Breast Cancer From Chennai, South India, 1990–1999","note":"International Journal of Radiation Oncology*Biology*Physics","from":"shanta-v","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas","note":"JCO","from":"mitchel-berger","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer","note":"Journal of Clinical Oncology","from":"ate-van-der-zee","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Sorafenib in advanced hepatocellular carcinoma (SHARP)","note":"NEJM","from":"josep-llovet","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Speeding up the evaluation of new agents in cancer","note":"JNCI","from":"mahesh-parmar","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Symptom concerns and quality of life in hepatobiliary cancers","note":"Oncology Nursing Forum","from":"virginia-sun","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Velvet: algorithms for de novo short read assembly using de Bruijn graphs","note":"Genome Research","from":"ewan-birney","refs":[]},{"group":"person-paper","date":"2008","precision":"year","title":"Vulnerability to heat-related mortality in Latin America: a case-crossover study in Sao Paulo, Brazil, Santiago, Chile and Mexico City, Mexico","note":"Int J Epidemiol","from":"victor-hugo-borja-aburto","refs":[]},{"group":"technology","date":"2008","precision":"year","title":"Bimatoprost for eyelash and eyebrow regrowth","note":"First use in humans or first approval, as the technology record states it.","from":"bimatoprost-eyelash-regrowth","refs":[]},{"group":"technology","date":"2008","precision":"year","title":"Confocal microscopy and optical coherence tomography for skin (VivaScope, VivoSight, deepLive)","note":"First use in humans or first approval, as the technology record states it.","from":"confocal-oct-skin-imaging","refs":[]},{"group":"technology","date":"2008","precision":"year","title":"CT body composition and sarcopenia measurement","note":"First use in humans or first approval, as the technology record states it.","from":"ct-body-composition-sarcopenia","refs":[]},{"group":"technology","date":"2008","precision":"year","title":"Hypofractionated radiotherapy","note":"First use in humans or first approval, as the technology record states it.","from":"hypofractionated-radiotherapy","refs":[]},{"group":"technology","date":"2008","precision":"year","title":"Pencil-beam scanning and intensity-modulated proton therapy","note":"First use in humans or first approval, as the technology record states it.","from":"intensity-modulated-proton-therapy","refs":[]},{"group":"technology","date":"2008","precision":"year","title":"Volumetric modulated arc therapy (VMAT)","note":"First use in humans or first approval, as the technology record states it.","from":"vmat","refs":[]},{"group":"trial","date":"2008","precision":"year","title":"ANGIOTAX reported","note":"Primary endpoint met: most patients progression-free at two months; responses mainly in cutaneous scalp and face disease.","from":"angiotax","refs":["angiosarcoma","vascular-tumours","sarcoma","paclitaxel"]},{"group":"trial","date":"2008","precision":"year","title":"EXTREME reported","note":"OS 10.1 vs 7.4 months; HR 0.80.","from":"extreme","refs":["head-and-neck","recurrent-metastatic-hnscc"]},{"group":"trial","date":"2008","precision":"year","title":"LACE (Lung Adjuvant Cisplatin Evaluation) pooled analysis reported","note":"Hazard ratio for death 0.89 (95 percent confidence interval 0.82 to 0.96), a 5.4 percent absolute five-year survival benefit; no benefit, and possible harm, in stage IA.","from":"lace-pooled-analysis","refs":["resectable-nsclc","cisplatin","vinorelbine","etoposide"]},{"group":"trial","date":"2008","precision":"year","title":"MNTX 302 reported","note":"Laxation within four hours of the first dose 48% vs 15% on placebo; laxation after two or more of the first four doses 52% vs 8% (P<0.001 for both).","from":"mntx-302","refs":["methylnaltrexone"]},{"group":"trial","date":"2008","precision":"year","title":"Photodynamic therapy against cryotherapy for superficial basal cell carcinoma reported","note":"Five-year recurrence 20 per cent after cryotherapy against 22 per cent after methyl aminolevulinate photodynamic therapy (p=0.86), with an excellent cosmetic outcome in 16 against...","from":"mal-pdt-versus-cryotherapy-superficial-bcc","refs":["basal-cell-carcinoma","skin-cancer","methyl-aminolevulinate"]},{"group":"trial","date":"2008","precision":"year","title":"RTOG 92-02 reported","note":"At 10 years, 24 extra months of goserelin improved disease-free survival (22.5 against 13.2 percent), disease-specific survival (88.7 against 83.9 percent) and distant metastasis (...","from":"rtog-9202","refs":["prostate","prostate-high-risk","goserelin","flutamide"]},{"group":"trial","date":"2008","precision":"year","title":"SHARP reported","note":"OS 10.7 vs 7.9 months, HR 0.69.","from":"sharp","refs":["hcc","hcc-advanced","sorafenib"]},{"group":"trial","date":"2008","precision":"year","title":"START-B (UK Standardisation of Breast Radiotherapy) reported","note":"10-year local-regional relapse 4.3% vs 5.5%; fewer late normal-tissue effects with 40 Gy in 15 fractions.","from":"start-b","refs":["breast-hr-positive","breast-her2-positive","tnbc","breast-cancer"]},{"group":"regulatory","date":"2008-12-19","precision":"day","title":"Imatinib: approval (US)","note":"Adjuvant GIST","from":"imatinib","refs":[]}]},"route":"/years/2008/","neighbours":{"year":[{"id":"2007","kind":"year","name":"2007 in oncology","route":"/years/2007/"},{"id":"2009","kind":"year","name":"2009 in oncology","route":"/years/2009/"}]}}